InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the full record of transactions filed by Ronsheim Matthew, Executive. Officer active across 2 companies, notably Entasis Therapeutics Holdings Inc.. Cumulatively, 8 reports have been logged. History available since 19 October 2021. The latest transaction was filed on 20 May 2024 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
8 of 8 declarations
Matthew Ronsheim is Chief, Pharma Sciences & MFG. at Entasis Therapeutics Holdings Inc. He is responsible for pharmaceutical sciences and manufacturing within the company. His technical expertise is crucial for developing high-quality products.